Menu
← Oncology Approval Tracker
FDA DECISION ·
Darzalex Faspro
daratumumab + hyaluronidase-fihj · Janssen Biotech
Open LinkedIn brief ↓1 min read · estimated
APPROVED USE
What FDA approved
Adults with multiple myeloma: with bortezomib, melphalan and prednisone when newly diagnosed and transplant-ineligible; with lenalidomide and dexamethasone when newly diagnosed and transplant-ineligible or after at least one line; with bortezomib and dexamethasone after at least one line; or alone after at least three lines including a proteasome inhibitor and an immunomodulatory drug, or with double-refractory disease.
LAMPGEN ANALYSIS
Why it matters
Provided a subcutaneous alternative to intravenous daratumumab in several settings.
What research teams should watch
Separate route-specific orders and maintain observation and transfusion compatibility procedures.
PRIMARY RECORDS